Oncology | Novartis

Media Release
Dec 08, 2023
Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions
Story
Dec 08, 2023
Shoulder to shoulder
Interior Page
Oncology
Media Release
Oct 26, 2023
Novartis confirms unconstrained supply for Pluvicto® and continues to significantly expand the number of treatment centers
Media Release
Oct 23, 2023
Novartis Pluvicto™ shows clinically meaningful and highly statistically significant rPFS benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer in the pre-taxane setting
Media Release
Oct 20, 2023
Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer
Media Release
Oct 05, 2023
Novartis to present new oncology data at ESMO 2023 demonstrating practice-changing innovation in advanced prostate and early breast cancer
Media Release
Sep 25, 2023
Novartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Media Release
Sep 14, 2023
Novartis Kisqali® reduced the risk of cancer recurrence while maintaining quality of life in patients diagnosed with early breast cancer
Story
Sep 08, 2023
Treatments for blood cancers and serious blood disorders are advancing rapidly – Novartis is helping lead the way
Media Release
Jun 09, 2023
Novartis unveils results from global patient and physician survey disrupting the notion that CML is a solved disease
Media Release
Jun 02, 2023
Novartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups